 Joshua Wisell
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2019 | 761 | 2.020 |
Why?
| | Sporotrichosis | 2 | 2018 | 4 | 1.280 |
Why?
| | Immunocompromised Host | 3 | 2019 | 195 | 1.260 |
Why?
| | Diagnostic Errors | 2 | 2016 | 148 | 0.880 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2018 | 218 | 0.710 |
Why?
| | Plasmablastic Lymphoma | 1 | 2019 | 6 | 0.660 |
Why?
| | Itraconazole | 1 | 2018 | 7 | 0.640 |
Why?
| | Dermatomycoses | 1 | 2018 | 7 | 0.640 |
Why?
| | Paget Disease, Extramammary | 1 | 2018 | 3 | 0.620 |
Why?
| | Opportunistic Infections | 1 | 2018 | 43 | 0.620 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 98 | 0.590 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2017 | 17 | 0.590 |
Why?
| | Transplant Recipients | 1 | 2019 | 140 | 0.580 |
Why?
| | Pathology, Surgical | 1 | 2016 | 7 | 0.550 |
Why?
| | Melanoma | 4 | 2017 | 629 | 0.550 |
Why?
| | Frozen Sections | 1 | 2016 | 24 | 0.540 |
Why?
| | Neurodermatitis | 1 | 2015 | 1 | 0.510 |
Why?
| | Foot Dermatoses | 1 | 2015 | 4 | 0.510 |
Why?
| | Acanthosis Nigricans | 1 | 2015 | 6 | 0.510 |
Why?
| | Hyperpigmentation | 1 | 2015 | 11 | 0.510 |
Why?
| | Minocycline | 1 | 2015 | 26 | 0.500 |
Why?
| | Acne Vulgaris | 1 | 2015 | 20 | 0.500 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 311 | 0.460 |
Why?
| | Granular Cell Tumor | 1 | 2014 | 7 | 0.460 |
Why?
| | SOXE Transcription Factors | 1 | 2014 | 17 | 0.450 |
Why?
| | Biomarkers, Tumor | 3 | 2017 | 1053 | 0.450 |
Why?
| | Scalp | 1 | 2013 | 29 | 0.430 |
Why?
| | Decidua | 1 | 2012 | 23 | 0.410 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2011 | 5 | 0.400 |
Why?
| | Cicatrix | 1 | 2012 | 50 | 0.400 |
Why?
| | Endometriosis | 1 | 2012 | 40 | 0.390 |
Why?
| | Skin Ulcer | 1 | 2011 | 13 | 0.390 |
Why?
| | Skin Diseases | 1 | 2012 | 122 | 0.360 |
Why?
| | Cesarean Section | 1 | 2012 | 169 | 0.360 |
Why?
| | Head and Neck Neoplasms | 1 | 2013 | 436 | 0.320 |
Why?
| | Biopsy | 4 | 2021 | 1040 | 0.290 |
Why?
| | Graft vs Host Disease | 3 | 2023 | 215 | 0.280 |
Why?
| | Glycogen | 1 | 2006 | 51 | 0.270 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1635 | 0.260 |
Why?
| | Brain Neoplasms | 1 | 2014 | 984 | 0.260 |
Why?
| | Exome | 2 | 2017 | 200 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1361 | 0.250 |
Why?
| | Hepatocytes | 1 | 2006 | 196 | 0.250 |
Why?
| | HIV Infections | 1 | 2018 | 2469 | 0.230 |
Why?
| | Humans | 26 | 2023 | 114756 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 193 | 0.220 |
Why?
| | Male | 15 | 2021 | 55579 | 0.220 |
Why?
| | Skin | 3 | 2021 | 659 | 0.200 |
Why?
| | Adult | 11 | 2021 | 30548 | 0.200 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 610 | 0.190 |
Why?
| | Skin Diseases, Vascular | 1 | 2021 | 8 | 0.190 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.180 |
Why?
| | Mutation | 3 | 2017 | 3350 | 0.180 |
Why?
| | Embolism | 1 | 2021 | 43 | 0.180 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.180 |
Why?
| | Vasculitis | 1 | 2021 | 70 | 0.180 |
Why?
| | Biopsy, Needle | 2 | 2018 | 181 | 0.170 |
Why?
| | Exanthema | 2 | 2018 | 74 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2023 | 429 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 584 | 0.150 |
Why?
| | Paint | 1 | 2017 | 7 | 0.150 |
Why?
| | Carcinoma | 1 | 2019 | 198 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.140 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 5 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 63 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 49 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 25 | 0.140 |
Why?
| | Necrosis | 2 | 2021 | 210 | 0.140 |
Why?
| | Intraoperative Period | 1 | 2016 | 50 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2017 | 108 | 0.140 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2017 | 299 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 179 | 0.120 |
Why?
| | Middle Aged | 8 | 2019 | 26757 | 0.120 |
Why?
| | Aged | 6 | 2019 | 19094 | 0.120 |
Why?
| | 4-Nitroquinoline-1-oxide | 1 | 2013 | 8 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 773 | 0.110 |
Why?
| | Prognosis | 2 | 2018 | 3334 | 0.110 |
Why?
| | Tongue Neoplasms | 1 | 2013 | 20 | 0.110 |
Why?
| | Stilbenes | 1 | 2013 | 36 | 0.110 |
Why?
| | Oximes | 1 | 2013 | 19 | 0.110 |
Why?
| | Smad4 Protein | 1 | 2013 | 34 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 398 | 0.110 |
Why?
| | Grape Seed Extract | 1 | 2013 | 41 | 0.110 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1340 | 0.110 |
Why?
| | Carcinogens | 1 | 2013 | 105 | 0.110 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 67 | 0.110 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 68 | 0.110 |
Why?
| | Neoplastic Stem Cells | 2 | 2013 | 334 | 0.110 |
Why?
| | Pyrimidinones | 1 | 2013 | 88 | 0.100 |
Why?
| | ras Proteins | 1 | 2013 | 138 | 0.100 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2013 | 175 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Pyridones | 1 | 2013 | 123 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 211 | 0.100 |
Why?
| | Mitotic Index | 1 | 2011 | 26 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2018 | 9089 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2016 | 632 | 0.100 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 528 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 44 | 0.090 |
Why?
| | Female | 12 | 2023 | 59507 | 0.090 |
Why?
| | Carcinoma, Lobular | 1 | 2011 | 44 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2012 | 1868 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 319 | 0.090 |
Why?
| | Antigens, CD20 | 1 | 2010 | 28 | 0.090 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 301 | 0.090 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 241 | 0.090 |
Why?
| | Estrogens | 1 | 2012 | 312 | 0.080 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 372 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2016 | 801 | 0.080 |
Why?
| | Risk Assessment | 1 | 2018 | 2973 | 0.080 |
Why?
| | Vipoma | 1 | 2008 | 1 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2008 | 61 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1796 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 449 | 0.070 |
Why?
| | Inclusion Bodies | 1 | 2006 | 24 | 0.070 |
Why?
| | Hepatitis B, Chronic | 1 | 2006 | 18 | 0.070 |
Why?
| | Apoptosis | 2 | 2013 | 2369 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1477 | 0.070 |
Why?
| | Cytoplasm | 1 | 2006 | 255 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 440 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2199 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1314 | 0.050 |
Why?
| | Carcinogenesis | 2 | 2013 | 180 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 732 | 0.050 |
Why?
| | Purpura | 1 | 2021 | 13 | 0.050 |
Why?
| | Fasciotomy | 1 | 2021 | 16 | 0.050 |
Why?
| | Tablets | 1 | 2021 | 36 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2021 | 22 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 854 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2021 | 201 | 0.050 |
Why?
| | Triazines | 1 | 2021 | 36 | 0.050 |
Why?
| | Fingers | 1 | 2021 | 83 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2021 | 284 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 12515 | 0.040 |
Why?
| | Foreign Bodies | 1 | 2021 | 96 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 183 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 699 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 524 | 0.040 |
Why?
| | Pyrazoles | 1 | 2021 | 364 | 0.040 |
Why?
| | Patient Compliance | 1 | 2021 | 525 | 0.040 |
Why?
| | Lung Transplantation | 1 | 2019 | 246 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 138 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 6350 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 158 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 372 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 9 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 13 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2013 | 119 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 28 | 0.030 |
Why?
| | Tongue | 1 | 2013 | 67 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 232 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 167 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 947 | 0.030 |
Why?
| | Mice | 3 | 2013 | 14916 | 0.030 |
Why?
| | Child, Preschool | 1 | 2006 | 9079 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 338 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 229 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 91 | 0.030 |
Why?
| | Computational Biology | 1 | 2016 | 530 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 168 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 635 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 642 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 5525 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 437 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 295 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 320 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 192 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 261 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 138 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 460 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 228 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 561 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3005 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 743 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 706 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2010 | 127 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2010 | 207 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4420 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2008 | 60 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1951 | 0.020 |
Why?
| | Splenectomy | 1 | 2008 | 51 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1147 | 0.020 |
Why?
| | Acantholysis | 1 | 2007 | 2 | 0.020 |
Why?
| | Animals | 3 | 2013 | 31761 | 0.020 |
Why?
| | Child | 1 | 2006 | 18352 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 601 | 0.020 |
Why?
| | Pancreaticoduodenectomy | 1 | 2008 | 133 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 727 | 0.020 |
Why?
| | Pancreatectomy | 1 | 2008 | 171 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2196 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 386 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2010 | 769 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4710 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2557 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10463 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3416 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4521 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2269 | 0.010 |
Why?
|
|
Wisell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|